Lv41
782 积分 2022-10-10 加入
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective
19小时前
已完结
Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study
3个月前
已完结
Drug-Linkers in Antibody–Drug Conjugates: Perspective on Current Industry Practices
4个月前
已完结
Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody–Drug Conjugates
4个月前
已完结
Considerations for Starting Material Designation for Drug-Linkers in Antibody–Drug Conjugates
4个月前
已完结
Deriving acceptable limits for non-mutagenic impurities in medicinal products – Durational adjustments
4个月前
已完结
Volume of Distribution in Drug Design
5个月前
已完结
Development of a MMAE-based antibody-drug conjugate targeting B7–H3 for glioblastoma
6个月前
已完结
A multi-scale numerical study of monoclonal antibodies uptake by initial lymphatics after subcutaneous injection
6个月前
已完结
Predicting Human Bioavailability of Subcutaneously Administered Fusion Proteins and Monoclonal Antibodies Using Human Intravenous Clearance or Antibody Isoelectric Point
6个月前
已完结
皖公网安备34019202002308
